| Abbott (23) |  |
| Amgen (10) | |
| Astra-merck (6) | |
| Bayer (41) | |
| Boehringer-ingelheim (1) | |
| Bristol-myers-squibb (5) | |
| Dupont-merck (14) | |
| Eli lilly (5) | |
| Genentech (5) | |
| Genzyme (5) | |
| Glaxosmithkline (26) | |
| Hoechst-marion-roussel (4) | |
| Pasteur-merieux (8) | |
| Pfizer (22) | |
| Pharmaceutical industry (36) | |
| Pharmaceutical laboratory (1) | |
| Pharmacyclics (1) | |
| Roche pharmaceuticals (16) | |
| Sanofi-aventis (6) | |
| Stallergenes (1) | |
| Whitehall laboratories (3) | |
Astrazeneca has hired Pfizer's research and development (R&d) chief, Martin Mackay, to take the helm of its own R&d programme.
Pfizer and Astrazeneca are both restructuring their R&d programmes to replenish pipelines and cut costs.
and Astrazeneca, will also design software to make the results useful to researchers and clinicians.
Bristol-myers squibb and Astrazeneca, are teaming up to acquire the biotech firm Amylin, based in San diego, California, for US$5. 3 Â billion (or $7 Â billion with existing contractual obligations).
Amylin will receive $3. 4 Â billion from London-based Astrazeneca, and the two firms will share profits and losses from Amylin s drugs pipeline.
Among companies, Astrazeneca had the most public-private partnerships, including its deal with Sweden s Karolinska Institute to create a US$100-million cardiac-research centre.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011